Sofosbuvir treatment and hepatitis C virus infection

Table 1 Summary of phase 3 study for hepatitis C virus genotype 1-infected patients

Study name	Population	Treatment	Duration (wk)	n	LC (%)	SVR12 (%)
						All	Non-LC	LC
NEUTRINO	Naïve	SOF/PEG-IFN/RBV	12	291	-	89	-	81
ION-1	Naïve	SOF/LDV	12	210	16	99	100	97
		SOF/LDV/RBV	12	216	15	97	97	100
		SOF/LDV	24	214	15	98	99	97
		SOF/LDV/RBV	24	214	17	99	99	100
ION-3	Naïve	SOF/LDV	8	214	0	94	94	-
		SOF/LDV/RBV	8	216	0	93	93	-
		SOF/LDV	12	216	0	95	95	-
Japanese study	Naïve	SOF/LDV	12	83	16	100	100	100
		SOF/LDV/RBV	12	83	14	96	97	92
ION-2	Experienced	SOF/LDV	12	20	94	95	86	20
		SOF/LDV/RBV	12	20	96	100	82	20
		SOF/LDV	24	20	99	99	100	20
		SOF/LDV/RBV	24	20	99	99	100	20
Japanese study	Experienced	SOF/LDV	12	32	100	100	100	32
		SOF/LDV/RBV	12	25	100	100	100	25

LC: Liver cirrhosis; SVR12: Sustained virologic response at 12 wk; Naïve: Treatment-naïve; Experienced: Treatment-experienced; SOF: Sofosbuvir; LDV: Ledipasvir; PEG-IFN: Peginterferon; RBV: Ribavirin.